
This review synthesizes the past 5 years of research on individuals with perinatally acquired HIV-1 (PHIV) with a focus on evaluating the proviral reservoir landscape and associated immunological correlates. We found that the age at the time of study shapes the questions being addressed and insights gained from infancy through adulthood in PHIV cohorts where ART timing shapes immune development and reservoir establishment. In infants and newborns, there has been more frequent antiretroviral therapy interruption (ATI) studies, with and without immunotherapy (e.g., bNAbs), aiming to replicate Mississippi Baby-like control in early-treated infants with small reservoirs. In long-term suppressed adolescents and adults with PHIV, work increasingly focuses on characterization of the long-lived HIV-1 reservoir and defining immunological correlates of smaller, less diverse reservoirs in order to predict post-treatment control. Understanding perinatal HIV-1 infection by life stage is essential for guiding future intervention and cure research.
This review examines the bidirectional relationship between chemsex and HIV pre-exposure prophylaxis (PrEP): chemsex practice among individuals engaged with PrEP, and PrEP awareness, willingness, and uptake among those who practice chemsex. We introduce the concept of a prevention divide, a persistent gap between elevated HIV/STI risk and sustained engagement with biomedical prevention, shaped by psychosocial, behavioural, and structural factors. Individuals who engage in chemsex, often characterized by polysubstance use, condomless sex, and multiple partners, frequently exhibit high risk for HIV and STI acquisition, yet this awareness does not consistently translate into preventive action. Despite elevated HIV vulnerability, barriers such as cost, poor mental health, and structural exclusion continue to hinder engagement with PrEP. Longitudinal and cross-sectional studies from Europe, Asia, North and South America confirm strong associations between chemsex and bacterial STIs, while also highlighting increased PrEP acceptability and adherence among high-risk subgroups. Yet, consistent with the disproportionate HIV burden among MSM, the existing literature remains largely centred on this population, leaving disaggregated data on heterosexuals, transgender people, sex workers, and migrants comparatively scarce. Across both directions, the gap is rarely one of motivation: chemsex users are frequently receptive to PrEP, and PrEP users who practice chemsex often engage strongly in the short term, but rather one of sustained structural support, as cost, fragmented services, and limited provider training determine whether prevention translates into durable protection. Integrated, person-centred care combining behavioural health, harm reduction, and social support is vital to closing this divide equitably.
This review summarizes the key factors that influence CD4 recovery after antiretroviral therapy (ART) initiation in people with HIV (PWH). Several immunomodulatory agents have been tested in clinical trials as adjuncts to ART. While interleukin-2 and interleukin-7 produce transient CD4 increases, and agents such as recombinant human growth hormone, maraviroc, and others show modest or variable effects, most have not demonstrated clear clinical benefit. Emerging evidence underscores the need for personalized approaches, reliable biomarkers to predict CD4 recovery, and novel adjunctive therapies such as gene editing and mitochondrial-targeted interventions. Poor CD4 recovery contributes to higher rates of non-AIDS complications. We highlight clinical determinants (e.g., timing of ART initiation), biological influences (e.g., epigenetic modifications), cellular factors (e.g., mitochondrial dysfunction), and modifiable socioeconomic determinants (e.g. nutrition, substance use). Addressing factors impacting CD4 recovery is critical to improving long-term outcomes for PWH.
This narrative Review provides a synthesis of the current evidence on the epidemiology, mechanisms, and interventions for unhealthy alcohol use (UAU) in people living with HIV (PLWH). UAU and HIV form a syndemic relationship that negatively impacts HIV treatment outcomes, including reduced antiretroviral therapy (ART) adherence and viral suppression, and increased mortality. Despite the high prevalence rates of UAU among PLWH, screening and treatment gaps persist in this population. Behavioral factors—such as intentional ART skipping and condomless sex—and structural barriers, including poverty and alcohol-related stigma, further worsen HIV outcomes. Moreover, underutilized screening tools and provider hesitancy continue to hinder alcohol treatment for PLWH. Consequently, UAU remains underdiagnosed in PLWH, while those diagnosed are less likely to receive treatment. Promising interventions such as pharmacotherapy (e.g., naltrexone), cognitive behavioral interventions (e.g., motivational interviewing and contingency management), and combination economic empowerment programs (e.g. conditional and non-conditional cash transfers) are currently inconsistently implemented. Action is urgently needed to implement and standardize UAU screening and management in PLWH. Addressing this syndemic phenomenon demands a holistic approach combining medical/clinical, behavioral, and structural solutions to improve survival and quality of life for PLWH.
This narrative review examines the evolving epidemiology of HIV in Pakistan from 1987 to 2026, focusing on temporal trends among key populations, geographic hotspots, emerging pediatric infections, and health-system gaps affecting epidemic control. Evidence indicates a persistent concentrated epidemic, with the highest burden among people who inject drugs and continuing transmission among sex workers, transgender populations, and prisoners. HIV transmission remains geographically heterogeneous, with major urban hotspots in Karachi and cities across Punjab. Recent pediatric outbreaks have introduced an important healthcare-associated dimension, with unsafe medical practices and weaknesses in infection prevention and control emerging as major concerns. Pakistan’s HIV epidemic remains concentrated but is becoming increasingly complex. Persistent transmission among key populations, geographic expansion, pediatric infections, and substantial gaps in diagnosis, treatment, and viral suppression highlight the need for strengthened surveillance, prevention, infection control, and continuity of HIV care.